Meeting Report
27–30 June 2017 Manila, Philippines
The purpose of the landscape analysis is ultimately to facilitate improved engagement of private providers, thereby contributing to universal access to quality and affordable TB care and the end of the TB epidemic. It focuses on the role of private for-profit providers and on specific challenges and... experiences in engaging them for TB prevention and care.
more
Moving from accelerated burden reduction to malaria elimination in Zambia
The report offers an analysis of the broader challenges to securing humanitarian action and recommends areas for improvement. This study will contribute to improving the way humanitarians ‘do business’ in complex
security environments. Document also available in French, Arabic and Spanish.
This compendium collates current tools and resources on quality improvement developed by the WHO Service Delivery and Safety Department and provides examples of how the tools and resources have been applied in country settings. The target audience for this document are ministries of health, facility... quality improvement teams, researchers and development agencies. WHO technical programmes, regional and country offices can also use the document in their technical cooperation work with the identified audience. Those working to improve the quality of health service delivery can also make good use of this resource
more
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
Results and Lessons Learned from CapacityPlus 2009-2015
2nd edition .
This Framework applies to the sharing of H5N1 and other influenza viruses with human pandemic potential and the sharing of benefits. This Framework does not apply to seasonal influenza viruses or other non-influenza pathogens or biological substances that may be contained in clinical ...specimens shared under this Framework
This second edition of the Pandemic Influenza Preparedness (PIP) Framework reflects an amendment to Annex 2, Standard Material Transfer Agreement 2, Footnote 1, that was adopted by the Seventy-second World Health Assembly in May 2019.The amendment clarifies that, under certain circumstances, the indirect use of PIP Biological Materials will require the conclusion of an SMTA2. The amendment is in effect from the closure of the Seventy-second World Health Assembly (28 May 2019).
more